• Mezzacappa C, Kim NJ, Vutien P, Kaplan DE, Ioannou GN, Taddei TH. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open. 2024 Jul 1; 7(7):e2420963.
• Talal AH, Markatou M, Liu A, Perumalswami PV, Dinani AM, Tobin JN, Brown LS. Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial. JAMA. 2024 Apr 23; 331(16):1369-1378.
• Chen PH, Truong J, Kawamoto J, Bhattacharya D, Patel A. Outcomes and Barriers Associated with Telehealth-Based Hepatitis C Treatment During Early Phases of the COVID-19 Pandemic. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. 2024 Mar 1; 41(3):88-92.
• Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Ninburg M, Kubiniec RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug and Alcohol Dependence Reports. 2024 Mar 1; 10:100213.
• Liang X, Justice AC, Marconi VC, Aouizerat BE, Xu K. Co-occurrence of injection drug use and hepatitis C increases epigenetic age acceleration that contributes to all-cause mortality among people living with HIV. Epigenetics. 2023 Dec 1; 18(1):2212235.

» View more Citations

• High Virologic Cure Rates for Hepatitis C Virus among Veterans with Opioid Use Disorder Treated with Elbasvir/Grazoprevir
  Elbasvir (EBR)/grazoprevir (GZR) is a fixed-dose combination treatment for hepatitis C virus (HCV). This study sought to evaluate the real-world effectiveness of EBR/GZR among Veterans with HCV genotype (GT) 1 who also had a diagnosis of opioid use disorder (OUD). Findings showed that high rates of virologic cure were achieved among VA patients with HCV, OUD, and multiple comorbidities, including ...
  
  Date: January 25, 2022
• Veterans Advocate Treating “Sickest First” When Discussing Limited Resources for Hepatitis C Treatment
  Investigators in this study used Democratic Deliberation (DD) methods as a proof of concept for informing policy decisions related to the allocation of scarce resources for treatment of chronic hepatitis C virus in VA. Findings showed that most Veterans endorsed a sickest-first policy over a first-come-first-served policy, emphasizing the ethical and medical appropriateness of treating the sickest...
  
  Date: May 1, 2020
• VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
  This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
  
  Date: March 7, 2018
• HCV-Related Complications Increasing among Women Veterans
  This study examined gender-related differences in the incidence and prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular cancer (HCC) between 2000 and 2013. Findings showed that the incidence and prevalence of hepatitis C virus (HCV) complications was higher in men than in women. However, the rate of increase in the incidence rates of cirrhosis and decompensated cirrhosis among HCV...
  
  Date: November 1, 2017
• Direct-Acting Antiviral Agents Reduce Risk of Hepatocellular Cancer among Veterans with Hepatitis C
  This study examined the risk of hepatocellular cancer (HCC) following sustained virological response (SVR) among 22,500 Veterans with hepatitis C virus (HCV) who received directing-acting antivirals (DAA) treatment at any of 129 VA hospitals between January and December 2015. Findings showed that in Veterans treated with DAAs, SVR was associated with a 76% reduction in the risk of developing hepat...
  
  Date: October 1, 2017

» View more Publication Briefs

» View more Studies

Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C (03-27-2013)

» View more Cyberseminars

Videos

There are currently no videos for this topic.

Podcasts

There are currently no podcasts for this topic.

Other Resources

• Visit the VA’s health information page for Veterans on hepatitis C.
• Learn more about the relationship between substance use disorders and hepatitis C through the “Promoting Value & Access in VA's Substance Use Disorder Services” CREATE
• Learn more about the Quality Enhancement Research Initiative’s Bridging the Care Continuum project focusing on liver disease outreach.